Eid M El-Shafey1, Said H Abdou, Mohamed M Shareef. 1. Division of Nephrology, Department of Internal Medicine, Tanta University Hospitals, Tanta University, Tanta, Egypt. shafey70@yahoo.com
Abstract
BACKGROUND: Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis. The aim of this study was to evaluate the efficacy of MMF compared with IVC in the induction therapy of proliferative lupus nephritis. METHODS: We randomly assigned 47 patients with newly diagnosed active proliferative lupus nephritis class III or IV toopen-label oral MMF 2 g/day for 6 months or intravenous cyclophosphamide 0.5-1 g/m(2) monthly for 6 months in addition to corticosteroids. RESULTS: In the intention-to-treat analysis, 14 of the 24 patients (58.33%) receiving MMF and 12 of the 23 patients receiving cyclophosphamide (52.17%) had remission (P = 0.48); complete remission occurred in 6 of the 24 patients (25%) and 5 of the 23 patients (21.74%), respectively (P = 0.53). Improvements in packed cell volume, the erythrocyte sedimentation rate, anti-double-stranded DNA antibodies titer (anti-dsDNA), serum complement, proteinuria, urinary activity, renal function, serum soluble interleukin-2 receptor alpha concentration and the systemic lupus activity measure score were similar in both groups. Two patients assigned to MMF and another patient assigned to IVC developed end-stage renal failure with commencement of dialysis. Adverse events were similar. Major infections occurred in two patients in each group. There was no difference in gastrointestinal side effects, but more diarrhea occurred in those receiving MMF. CONCLUSION: In this 24-week trial, MMF or IVC combined with corticosteroids demonstrated equal efficacy in inducing remission of proliferative lupus nephritis.
RCT Entities:
BACKGROUND: Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis. The aim of this study was to evaluate the efficacy of MMF compared with IVC in the induction therapy of proliferative lupus nephritis. METHODS: We randomly assigned 47 patients with newly diagnosed active proliferative lupus nephritis class III or IV to open-label oral MMF 2 g/day for 6 months or intravenous cyclophosphamide 0.5-1 g/m(2) monthly for 6 months in addition to corticosteroids. RESULTS: In the intention-to-treat analysis, 14 of the 24 patients (58.33%) receiving MMF and 12 of the 23 patients receiving cyclophosphamide (52.17%) had remission (P = 0.48); complete remission occurred in 6 of the 24 patients (25%) and 5 of the 23 patients (21.74%), respectively (P = 0.53). Improvements in packed cell volume, the erythrocyte sedimentation rate, anti-double-stranded DNA antibodies titer (anti-dsDNA), serum complement, proteinuria, urinary activity, renal function, serum soluble interleukin-2 receptor alpha concentration and the systemic lupus activity measure score were similar in both groups. Two patients assigned to MMF and another patient assigned to IVC developed end-stage renal failure with commencement of dialysis. Adverse events were similar. Major infections occurred in two patients in each group. There was no difference in gastrointestinal side effects, but more diarrhea occurred in those receiving MMF. CONCLUSION: In this 24-week trial, MMF or IVC combined with corticosteroids demonstrated equal efficacy in inducing remission of proliferative lupus nephritis.
Authors: Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: A Hurtado; C Asato; E Escudero; C S Stromquist; J Urcia; M E Hurtado; S de La Cruz; M H Wener; R Zavala; R J Johnson Journal: Nephron Date: 1999 Impact factor: 2.847
Authors: Mónica Fernández; Graciela S Alarcón; Jaime Calvo-Alén; Rosa Andrade; Gerald McGwin; Luis M Vilá; John D Reveille Journal: Arthritis Rheum Date: 2007-05-15
Authors: Michael Walsh; Matthew James; David Jayne; Marcello Tonelli; Braden J Manns; Brenda R Hemmelgarn Journal: Clin J Am Soc Nephrol Date: 2007-08-08 Impact factor: 8.237
Authors: D D Gladman; C H Goldsmith; M B Urowitz; P Bacon; C Bombardier; D Isenberg; K Kalunian; M H Liang; P Maddison; O Nived Journal: J Rheumatol Date: 1994-08 Impact factor: 4.666
Authors: David J Tunnicliffe; Suetonia C Palmer; Lorna Henderson; Philip Masson; Jonathan C Craig; Allison Tong; Davinder Singh-Grewal; Robert S Flanc; Matthew A Roberts; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2018-06-29